Cardiac Amyloidosis is an increasingly recognized cause of heart failure, arrhythmias, and unexplained left ventricular thickening, often misdiagnosed as hypertensive heart disease or hypertrophic cardiomyopathy. This session explores how to recognize red-flag features, select appropriate diagnostic tests, and coordinate multidisciplinary evaluation. Participants will learn how to differentiate transthyretin (ATTR) from light-chain (AL) amyloidosis, understand the prognostic implications of each, and apply targeted treatment strategies. By focusing on practical case scenarios and structured pathways, this session equips clinicians to improve detection and management of this underdiagnosed condition.

As awareness grows, many professionals search for a cardiology conference to gain clarity on when and how to screen patients. This session reviews the roles of echocardiography, cardiac MRI, bone scintigraphy, and laboratory testing in the diagnostic algorithm. Attendees will see how characteristic imaging patterns, abnormal strain findings, and extracardiac clues point toward amyloid involvement. The session emphasizes the importance of early diagnosis, given the availability of disease-modifying therapies and evolving treatment options.

A central theme is managing amyloid cardiomyopathy across the continuum of care. Participants will explore how to optimize heart failure therapy while avoiding drugs that may worsen symptoms in amyloid patients, such as certain afterload-reducing agents. The session discusses tafamidis and other transthyretin-targeted therapies, chemotherapy for AL amyloidosis, and referral criteria for transplant or advanced heart failure therapies. Practical guidance is provided on coordinating cardiology, hematology, genetics, and supportive care teams to deliver integrated, patient-centered management.

The session also addresses patient communication, genetic counseling, and long-term follow-up. Attendees will learn how to explain the diagnosis and prognosis clearly, discuss family screening where appropriate, and set expectations regarding therapy goals. By the end, clinicians will be better prepared to suspect cardiac amyloidosis earlier, choose the right investigations, and offer timely, evidence-based treatment strategies that can change the trajectory of this once uniformly fatal disease.